Co-led Diagonal Therapeutics' oversubscribed $125M Series B alongside Janus Henderson Investors; Partner Paulina Hill joined the board.
Diagonal Therapeutics is a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, focusing on hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH)
Diagonal Therapeutics is a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, focusing on hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH).